The Beacon

The Beacon

by

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Recent Episodes

  • Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

    6 years ago
  • Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)

    6 years ago
  • Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

    6 years ago
  • What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

    6 years ago
  • The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

    6 years ago
  • Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

    6 years ago
  • The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

    6 years ago
  • The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

    6 years ago
  • Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

    6 years ago
  • Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

    6 years ago